Payment overview · 2025
General Payments
$30,887.18
56 reported records · 14 companies
Healthcare provider profile · identity verified
Robert R Mendes, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · RALEIGH, NC · NPI 1407941784
Verified facts
What the public records show
CMS Open Payments records show Robert R Mendes, MD received $30,887.18 in general payments during 2025 across 56 reported records.
Medtronic, Inc. accounted for 69.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21,540.28 | 69.7% | 26 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $3,924.83 | 12.7% | 4 | 2025 |
| Contego Medical, Inc | Unresolved — no canonical attribution shown | $2,225.00 | 7.2% | 2 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $1,666.67 | 5.4% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $513.08 | 1.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $502.77 | 1.6% | 5 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $167.24 | 0.5% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $136.43 | 0.4% | 6 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $59.13 | 0.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $54.67 | 0.2% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $47.09 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.46 | 0.1% | 1 | 2025 |
| Sirtex Medical Inc | Unresolved — no canonical attribution shown | $15.81 | 0.1% | 1 | 2025 |
| Flowphysix Inc | Unresolved — no canonical attribution shown | $15.72 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,900.00 | 4 |
| Consulting Fee | $4,791.67 | 3 |
| Honoraria | $3,916.67 | 2 |
| Food and Beverage | $2,219.89 | 42 |
| Travel and Lodging | $1,058.95 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $5,890.98 | 8 | 2025 |
Source payment records
|
|||||
| Asahi Coronary Wires Normalized: asahi coronary wires |
Device | ASAHI INTECC USA, INC. | $2,253.63 | 2 | 2025 |
Source payment records
|
|||||
| Neuroguard Direct Normalized: neuroguard direct |
Device | Contego Medical, Inc | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $1,666.67 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $1,666.67 | 1 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $1,666.67 | 1 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $1,666.67 | 1 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $1,666.67 | 1 | 2025 |
Source payment records
|
|||||
| MO.MA ULTRA Normalized: mo ma ultra |
Device | Medtronic, Inc. | $971.21 | 10 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $513.08 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $502.77 | 5 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $134.86 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $106.25 | 5 | 2025 |
Source payment records
|
|||||
| AZUR CX DETACHABLE Normalized: azur cx detachable |
Device | Terumo Medical Corporation | $59.13 | 1 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $53.09 | 4 | 2025 |
Source payment records
|
|||||
| CARPENTIER-EDWARDS PHYSIO II ANNULOPLASTY RING Normalized: carpentier edwards physio ii annuloplasty ring |
Device | Edwards Lifesciences Corporation | $47.09 | 1 | 2025 |
Source payment records
|
|||||
| Direxion Normalized: direxion |
Device | Boston Scientific Corporation | $30.18 | 1 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $29.00 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $25.67 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| LAVA LES (Liquid Embolic System) Normalized: lava les liquid embolic system |
Device | Sirtex Medical Inc | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| FLOWRUNNER Normalized: flowrunner |
Device | Flowphysix Inc | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $12.32 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $12.09 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis Normalized: gore viabahn endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $7.97 | 1 | 2025 |
Source payment records
|
|||||
| Asahi Interventional Radiology Wires Normalized: asahi interventional radiology wires |
Device | ASAHI INTECC USA, INC. | $4.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 140 | 43 |
| Eliquis | Apixaban | 71 | 16 |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30,887.18 · 56 records | Medtronic, Inc. | ABRE, AZUR CX DETACHABLE, Alto Abdominal Stent Graft System, Asahi Coronary Wires, Asahi Interventional Radiology Wires, Asahi Peripheral Vascular Wires, CARPENTIER-EDWARDS PHYSIO II ANNULOPLASTY RING, Direxion, ESPRIT, FLOWRUNNER, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE VIABAHN Endoprosthesis, GORE VIABAHN Endoprosthesis with Heparin, GORE VIABAHN VBX Balloon Expandable Endo, General - Atherectomy, IGT Devices Undivided, IN.PACT ADMIRAL, LAVA LES (Liquid Embolic System), MO.MA ULTRA, Neuroguard Direct, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, REPATHA, SUPERA, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error